EANS-Adhoc: Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG start partial sale of Marinomed shares by way of an accelerated bookbuilding EAE

Tuesday, 15. October 2019 17:37
--------------------------------------------------------------------------------
  Disclosed inside information pursuant to article 17 Market Abuse Regulation
  (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
  The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital Measures
15.10.2019

Vienna - Marinomed Biotech AG: aws Mittelstandsfonds Beteiligungs GmbH & Co. KG
and Invest Unternehmensbeteiligungs AG start partial sale of Marinomed shares by
way of an accelerated bookbuilding of up to 95,000 shares (plus a possible
upsize option of up to additional 45,000 shares)

Marinomed Biotech AG (the "Company") announces that the Company was informed by
the two shareholders aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws
Mittelstandsfonds") and Invest Unternehmensbeteiligungs AG ("Invest AG") on 15
October 2019 that aws Mittelstandsfonds and Invest AG intend to sell in total up
to 95,000 Marinomed shares, ISIN ATMARINOMED6, plus an upsize alternative of up
to further 45,000 Marinomed shares from their holdings through an accelerated
bookbuilding transaction (the "Transaction").

The following information, put in quotation marks, is taken from the notfication
of the Company by aws Mittelstandsfonds and Invest AG:

"NOT FOR DISTRIBUTION OR PUBLICATION, EITHER DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES OF AMERICA, THE UNITED KINGDOM, CANADA, JAPAN OR AUSTRALIA.

aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws Mittelstandsfonds") and
Invest Unternehmensbeteiligungs AG ("Invest AG") hereby announce that today, 15
October 2019, aws Mittelstandsfonds and Invest AG have decided to sell Marinomed
Biotech AG shares, ISIN ATMARINOMED6, from their holdings to institutional
investors by means of an accelerated bookbuilding transaction (the "ABB"). Erste
Group Bank AG has been appointed to place the Marinomed shares through the ABB
and acts as the sole bookrunner.

aws Mittelstandsfonds and Invest AG intend to sell in total up to 95,000
Marinomed shares through the ABB. This corresponds to 6.5 per cent. of the share
capital of the Company. aws Mittelstandsfonds and Invest AG reserve the right to
decide - in consultation with Erste Group Bank AG as sole bookrunner - on
selling up to 45,000 additional Marinomed shares (corresponding to approximately
3.1 per cent. of the share capital of the Company) in the event of strong demand
(upsize alternative).

The books for the ABB are opened immediately. Information on the pricing and
allocation of Marinomed shares under the ABB is expected to be published
immediately after closing of the books. aws Mittelstandsfonds and Invest AG
reserve the right to change the conditions and timeline of the ABB at any time.

If all offered shares (including the upsize alternative) are placed through the
ABB, aws Mittelstandsfonds and Invest AG would still hold approximately 2.3 per
cent. and approximately 2.4 per cent., respectively, of the share capital of
Marinomed Biotech AG. For these shares (as well as for any shares not placed
under the ABB), the lock-up commitment of aws Mittelstandsfonds and Invest AG,
which was entered into as part of the IPO, will continue to apply.

Disclaimer:

This announcement constitutes neither an offer to buy securities nor a
solicitation of an offer to buy securities in the United States of America,
Germany, Austria or other countries. The securities are not sold or offered to
be sold in the United States of America under the rules of the US Securities Act
of 1933, as amended.

A public offer of the securities is neither made in Austria nor in any other
jurisdiction. Any offer of shares under the ABB shall be made solely on the
basis of an exemption from the obligation to publish a prospectus in accordance
with Article 1 (4) of Regulation (EU) 2017/1129 of the European Parliament and
of the Council of 14 June 2017 (the "Prospectus Regulation") and is exclusively
intended for qualified investors within the meaning of Article 2 (e) of the
Prospectus Regulation. Offers to purchase the securities by persons other than
qualified investors within the meaning of Article 2 (e) of the Prospectus
Regulation will be rejected without exception."

Further inquiry note:

Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria 
T +43 (0)1 250 77 4460 
E-Mail: eva.prieschl@marinomed.com 
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement                         euro adhoc
--------------------------------------------------------------------------------

issuer:       Marinomed Biotech AG
              Veterinärplatz 1
              A-1210 Wien
phone:        0043250774460
FAX:          0043250774493
mail:         office@marinomed.com
WWW:          www.marinomed.com
ISIN:         ATMARINOMED6, AT0000A1WD52
indexes:      
stockmarkets: Wien
language:     English

EAX0003    2019-10-15/17:37

Related Links: Marinomed Biotech AG
Author:
Ad-hoc-Mitteilung übermittelt durch euro adhoc.
Für den Inhalt ist der Emittent verantwortlich.